keyword
MENU ▼
Read by QxMD icon Read
search

Psma

keyword
https://www.readbyqxmd.com/read/29209626/neovascular-prostate-specific-membrane-antigen-expression-is-associated-with-improved-overall-survival-under-palliative-chemotherapy-in-patients-with-pancreatic-ductal-adenocarcinoma
#1
Katharina Stock, Konrad Steinestel, Rebekka Wiesch, Jan-Henrik Mikesch, Anna Hansmeier, Marcel Trautmann, Nora Beller, Jan Rehkämper, Eva Wardelmann, Birthe Heitkötter, Wolfgang Hartmann, Jan Sperveslage, Sebastian Huss
Aims: Expression of PSMA (prostate-specific membrane antigen) has been demonstrated in various cancers, including pancreatic ductal adenocarcinoma (PDAC). However, PSMA expression in PDAC-associated neovasculature has so far not been systematically analyzed. Methods and Results: We analyzed PSMA expression in 81 PDAC tissue samples from 61 patients. Microvessel density (MVD) was assessed by software-based image analysis and showed a mean MVD of 63.7 microvessels/0...
2017: BioMed Research International
https://www.readbyqxmd.com/read/29201627/dual-color-emitting-carbon-nanodots-for-multicolor-bioimaging-and-optogenetic-control-of-ion-channels
#2
Hyemin Kim, Yoonsang Park, Songeun Beack, Seulgi Han, Dooyup Jung, Hyung Joon Cha, Woosung Kwon, Sei Kwang Hahn
The development of intrinsically multicolor-emitting carbon nanodots (CNDs) has been one of the great challenges for their various fields of applications. Here, the controlled electronic structure engineering of CNDs is performed to emit two distinct colors via the facile surface modification with 4-octyloxyaniline. The so-called dual-color-emitting CNDs (DC-CNDs) can be stably encapsulated within poly(styrene-co-maleic anhydride) (PSMA). The prepared water-soluble DC-CNDs@PSMA can be successfully applied to in vitro and in vivo dual-color bioimaging and optogenetics...
November 2017: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
https://www.readbyqxmd.com/read/29199391/variations-in-the-practice-of-molecular-radiotherapy-and-implementation-of-dosimetry-results-from-a-european-survey
#3
Katarina Sjögreen Gleisner, Emiliano Spezi, Pavel Solny, Pablo Minguez Gabina, Francesco Cicone, Caroline Stokke, Carlo Chiesa, Maria Paphiti, Boudewijn Brans, Mattias Sandström, Jill Tipping, Mark Konijnenberg, Glenn Flux
BACKGROUND: Currently, the implementation of dosimetry in molecular radiotherapy (MRT) is not well investigated, and in view of the Council Directive (2013/59/Euratom), there is a need to understand the current availability of dosimetry-based MRT in clinical practice and research studies. The aim of this study was to assess the current practice of MRT and dosimetry across European countries. METHODS: An electronic questionnaire was distributed to European countries...
December 4, 2017: EJNMMI Physics
https://www.readbyqxmd.com/read/29191856/psma-11-derived-dual-labeled-psma-inhibitors-for-preoperative-pet-imaging-and-precise-fluorescence-guided-surgery-of-prostate-cancer
#4
Ann-Christin Baranski, Martin Schäfer, Ulrike Bauder-Wüst, Mareike Roscher, Jana Schmidt, Esther Stenau, Tobias Simpfendörfer, Dogu Teber, Lena Maier-Hein, Boris Hadaschik, Uwe Haberkorn, Matthias Eder, Klaus Kopka
Resection of tumor lesions using targeted dual-modality probes combining preoperative imaging with intraoperative guidance is of high clinical relevance and might considerably impact the outcome of prostate cancer therapy. This work aims at the development of dual-labeled prostate specific membrane antigen (PSMA)-inhibitors derived from the established positron emission tomography (PET)- and N,N'-bis[2-hydroxy-5-(carboxyethyl)benzyl]ethylenediamine-N,N'-diacetic acid (HBED-CC) based tracer 68Ga-Glu-urea-Lys(Ahx)-HBED-CC (68Ga-PSMA-11) to allow accurate intraoperative detection of PSMA-positive tumor lesions...
November 30, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29188305/synergistic-cytotoxicity-of-a-prostate-cancer-specific-immunotoxin-in-combination-with-the-bh3-mimetic-abt-737
#5
Theresa Noll, Susanne Schultze-Seemann, Irina Kuckuck, Marta Michalska, Philipp Wolf
In many tumors, including prostate cancer, anti-apoptotic members of the Bcl-2 family are overexpressed and cause cell death resistance, which is a typical hallmark of cancer. Different therapeutic approaches, therefore, aim to restore the death mechanisms for enhanced apoptosis. Our recombinant immunotoxin D7(VL-VH)-PE40 is composed of the scFv D7(VL-VH) against the prostate-specific membrane antigen (PSMA) on the surface of prostate cancer cells and of the cytotoxic domain of the bacterial toxin Pseudomonas Exotoxin A (PE40)...
November 29, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29188198/evaluation-of-the-changing-landscape-of-prostate-cancer-diagnosis-and-management-from-2005-to-2016
#6
Kirsten R Carlaw, Henry H Woo
Background: Approaches to prostate cancer (PCa) diagnosis and treatment have evolved significantly over past decades. There has been an increasing focus on minimizing overdiagnosis and overtreatment of clinically insignificant PCa. The objective of this study was to evaluate the changes in the diagnostic approach and initial treatment strategy that has evolved over time in an Australian urological private practice. Materials and methods: Men with newly diagnosed PCa were identified from the private practice electronic and paper medical records from 2005 to 2016 and data was consolidated into six groups of 2-year intervals...
December 2017: Prostate International
https://www.readbyqxmd.com/read/29188197/68ga-prostate-specific-membrane-antigen-positron-emission-tomography-computed-tomography-in-advanced-prostate-cancer-current-state-and-future-trends
#7
REVIEW
Cristian Udovicich, Marlon Perera, Michael S Hofman, Shankar Siva, Andres Del Rio, Declan G Murphy, Nathan Lawrentschuk
The early and accurate detection of prostate cancer is important to ensure timely management and appropriate individualized treatment. Currently, conventional imaging has limitations particularly in the early detection of metastases and at prostate-specific antigen (PSA) levels < 2.0 ng/mL. Furthermore, disease management such as salvage radiotherapy is best at low PSA levels. Thus, it is critical to capture the disease in the oligometastatic stage as disease progression and commencement of systemic therapies can be delayed by metastasis-directed therapy...
December 2017: Prostate International
https://www.readbyqxmd.com/read/29185010/preliminary-results-on-response-assessment-using-68ga-hbed-cc-psma-pet-ct-in-patients-with-metastatic-prostate-cancer-undergoing-docetaxel-chemotherapy
#8
Anna Katharina Seitz, Isabel Rauscher, Bernhard Haller, Markus Krönke, Sophia Luther, Matthias M Heck, Thomas Horn, Jürgen E Gschwend, Markus Schwaiger, Matthias Eiber, Tobias Maurer
PURPOSE: To investigate the value of 68Ga-HBED-CC PSMA (68Ga-PSMA) PET/CT for response assessment in metastatic castration-sensitive and castration-resistant prostate cancer (mCSPC and mCRPC) during docetaxel chemotherapy. METHODS: 68Ga-PSMA PET/CT was performed in seven mCSPC patients before and after six cycles of upfront docetaxel chemotherapy and in 16 mCRPC patients before and after three cycles of palliative docetaxel chemotherapy. Radiographic treatment response was evaluated separately on the 68Ga-PSMA PET and CT datasets...
November 28, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29181556/oligometastases-in-prostate-cancer-metabolic-response-in-follow-up-psma-pet-cts-after-hypofractionated-igrt
#9
René Baumann, Mark Koncz, Ulf Luetzen, Fabian Krause, Juergen Dunst
BACKGROUND: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMAPET/CT) is a new and evolving diagnostic method in prostate cancer with special impact on treatment planning in image-guided radiotherapy (IGRT). Initial results of metabolic response in repeated PSMA PET/CTs after hypofractionated IGRT for metastatic lesions are reported here. MATERIALS AND METHODS: Of 280 patients investigated with 68Ga-PSMA PET/CT in the period from 01/2014 through 12/2016 in the authors' department, patients were selected according to the following criteria: oligometastatic disease at initial PSMA PET/CT defined as not more than five metastatic lesions, hypofractionated IGRT to all lesions, no systemic therapy in the last 6 months and during follow-up, and at least one follow-up PSMA PET after radiotherapy...
November 27, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29170426/non-invasive-whole-body-detection-of-complement-activation-using-radionuclide-imaging-in-a-mouse-model-of-myocardial-ischaemia-reperfusion-injury
#10
Ehsan Sharif-Paghaleh, May Lin Yap, Sarah-Lena Puhl, Adam Badar, Julia Baguña Torres, Krisanat Chuamsaamarkkee, Florian Kampmeier, Richard A Smith, James Clark, Philip J Blower, Steven Sacks, Gregory E Mullen
Complement activation is a recognised mediator of myocardial ischaemia-reperfusion-injury (IRI) and cardiomyocytes are a known source of complement proteins including the central component C3, whose activation products can mediate tissue inflammation, cell death and profibrotic signalling. We investigated the potential to detect and quantify the stable covalently bound product C3d by external body imaging, as a marker of complement activation in heart muscle in a murine model of myocardial IRI. We used single-photon-emission-computed-tomography (SPECT) in conjunction with (99m)Technecium-labelled recombinant complement receptor 2 ((99m)Tc-rCR2), which specifically detects C3d at the site of complement activation...
November 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29166327/68ga-prostate-specific-membrane-antigen-uptake-in-gastrointestinal-stromal-tumor
#11
Tom Laurens, Fred Witjes, Marcel Janssen, Uta Flucke, Martin Gottardt
A 62-year-old man with recently diagnosed prostatic adenocarcinoma was referred for a whole-body Ga-prostate-specific membrane antigen (PSMA) PET/CT scan for staging. Although the scan did not reveal metastatic disease, it did reveal a PSMA-avid lesion in the upper abdomen located between the liver and the stomach. Histopathologic examination demonstrated a gastrointestinal stromal tumor. The lesion demonstrated increased uptake in the margins of the tumor with a central photopenic area, which we consider to be the typical pattern on PSMA images of a gastrointestinal stromal tumor, based on theoretical PSMA distribution in such a tumor and other reported cases...
January 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29158832/clinical-translation-and-first-in-human-use-of-44-sc-sc-psma-617-for-pet-imaging-of-metastasized-castrate-resistant-prostate-cancer
#12
Elisabeth Eppard, Ana de la Fuente, Martina Benešová, Ambreen Khawar, Ralph A Bundschuh, Florian C Gärtner, Barbara Kreppel, Klaus Kopka, Markus Essler, Frank Rösch
BACKGROUND: Various trivalent radiometals are well suited for labeling of DOTA-conjugated variants of Glu-ureido-based prostate-specific membrane antigen (PSMA) inhibitors. The DOTA-conjugate PSMA-617 has proven high potential in PSMA radioligand therapy (PSMA-RLT) of prostate cancer as well as PET imaging when labeled with lutetium-177 and gallium-68 respectively. Considering the relatively short physical half-life of gallium-68 this positron emitter precludes prolonged acquisition periods, as required for pre-therapeutic dosimetry or intraoperative applications...
2017: Theranostics
https://www.readbyqxmd.com/read/29149993/label-free-determination-of-prostate-specific-membrane-antigen-in-human-whole-blood-at-nanomolar-levels-by-magnetically-assisted-surface-enhanced-raman-spectroscopy
#13
Zuzana Chaloupková, Anna Balzerová, Jitka Bařinková, Zdenka Medříková, Pavel Šácha, Petr Beneš, Václav Ranc, Jan Konvalinka, Radek Zbořil
Prostate cancer is one of the most common cancers among men and can in its later stages cause serious medical problems. Due to the limited suitability of current diagnostic biochemical markers, new biomarkers for the detection of prostate cancer are highly sought after. An ideal biomarker should serve as a reliable prognostic marker, be applicable for early diagnosis, and be applicable for monitoring of therapeutic response. One potential candidate is glutamate carboxypeptidase II (GCPII), also known as prostate specific membrane antigen (PSMA), which has a promising role for direct imaging...
January 2, 2018: Analytica Chimica Acta
https://www.readbyqxmd.com/read/29149420/blood-clearance-and-occupational-exposure-for-177-lu-dotatate-compared-to-177-lu-psma-radionuclide-therapy
#14
Mohammad Abuqbeitah, Mustafa Demir, Lebriz Uslu-Beşli, Nami Yeyin, Kerim Sönmezoğlu
The main target of this work is to examine blood clearance and external exposure for (177)Lu-DOTATATE compared with new emerging (177)Lu-PSMA therapy. Blood clearance and radiation exposure of 31 patients treated with 5.5 ± 1.1 GBq (177)Lu-DOTATATE were compared to those of 23 patients treated with 7.4 GBq (177)Lu-PSMA. Dose rates were measured at several distances and time points up to 120 h after treatment. Blood samples were collected conjunctively after infusion. Caregiver's cumulative dose was measured by means of an OSL (optically stimulated luminescence) dosimeter for 4-5 days and medical staff's dose was also estimated using electronic personal dosimeters...
November 17, 2017: Radiation and Environmental Biophysics
https://www.readbyqxmd.com/read/29146698/characterization-of-site-specifically-conjugated-monomethyl-auristatin-e-and-duocarmycin-based-anti-psma-antibody-drug-conjugates-for-treatment-of-psma-expressing-tumors
#15
Susanne Lütje, Danny Gerrits, Janneke D Molkenboer-Kuenen, Ken Herrmann, Giulio Fracasso, Marco Colombatti, Otto C Boerman, Sandra Heskamp
Rationale: Prostate cancer (PCa) is the most common cancer in men worldwide. In general, PCa responds poorly to chemotherapy. Therefore, antibody-drug conjugates (ADCs) have been developed to specifically deliver highly cytotoxic drugs to the tumor. As the prostate-specific membrane antigen (PSMA) is overexpressed in PCa, it represents a promising target for ADC-based therapies. The aim of this study was to evaluate the therapeutic efficacy of site-specifically conjugated duocarmycin- and monomethyl auristatin E (MMAE)-based anti-PSMA ADCs with drug-antibody ratios (DARs) of 2 and 4...
November 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/29144944/re-impact-of-ga-68-psma-11-pet-on-management-in-patients-with-biochemically-recurrent-prostate-cancer
#16
Samir S Taneja
No abstract text is available yet for this article.
December 2017: Journal of Urology
https://www.readbyqxmd.com/read/29141866/prostate-specific-membrane-antigen-cleavage-of-vitamin-b9-stimulates-oncogenic-signaling-through-metabotropic-glutamate-receptors
#17
Charalambos Kaittanis, Chrysafis Andreou, Haley Hieronymus, Ninghui Mao, Catherine A Foss, Matthias Eiber, Gregor Weirich, Palak Panchal, Anuradha Gopalan, Juan Zurita, Samuel Achilefu, Gabriela Chiosis, Vladimir Ponomarev, Markus Schwaiger, Brett S Carver, Martin G Pomper, Jan Grimm
Prostate-specific membrane antigen (PSMA) or folate hydrolase 1 (FOLH1) is highly expressed on prostate cancer. Its expression correlates inversely with survival and increases with tumor grade. However, the biological role of PSMA has not been explored, and its role in prostate cancer remained elusive. Filling this gap, we demonstrate that in prostate cancer, PSMA initiates signaling upstream of PI3K through G protein-coupled receptors, specifically via the metabotropic glutamate receptor (mGluR). PSMA's carboxypeptidase activity releases glutamate from vitamin B9 and other glutamated substrates, which activate mGluR I...
November 15, 2017: Journal of Experimental Medicine
https://www.readbyqxmd.com/read/29137414/salvage-lymph-node-dissection-after-68-ga-psma-or-18-f-fec-pet-ct-for-nodal-recurrence-in-prostate-cancer-patients
#18
Annika Herlemann, Alexander Kretschmer, Alexander Buchner, Alexander Karl, Stefan Tritschler, Lina El-Malazi, Wolfgang P Fendler, Vera Wenter, Harun Ilhan, Peter Bartenstein, Christian G Stief, Christian Gratzke
The management of patients with biochemical recurrence (BCR) after definitive treatment for prostate cancer remains controversial. Our aim was to determine survival rates and complications of salvage lymph node dissection (sLND) in patients with recurrent prostate cancer after radical prostatectomy, while evaluating biochemical response (BR) with two different positron emission tomography/computed tomography (PET/CT) tracers used for preoperative imaging. sLND was performed in 104 patients diagnosed with isolated nodal recurrence on either (18)F-fluoroethylcholine ((18)F-FEC) or (68)Ga-PSMA-HBED-CC ((68)Ga-PSMA) PET/CT...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29134280/delayed-response-after-repeated-177-lu-psma-617-radioligand-therapy-in-patients-with-metastatic-castration-resistant-prostate-cancer
#19
Kambiz Rahbar, Martin Bögeman, Anna Yordanova, Maria Eveslage, Michael Schäfers, Markus Essler, Hojjat Ahmadzadehfar
PURPOSE: Radioligand therapy (RLT) using Lutetium-177 labeled PSMA-617 (Lu-PSMA) ligand is a new therapeutic option for salvage therapy in heavily pretreated patients with metastatic castration resistant prostate cancer. The aim of this retrospective study was to analyze response in patients receiving 3 cycles of Lu-PSMA. METHODS: Seventy-one patients (median age: 72 years; range 44-87) received 3 cycles of RLT with Lu-PSMA (mean administered activity: 6.016 ± 0...
November 13, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29134231/patterns-of-relapse-as-determined-by-68-ga-psma-ligand-pet-ct-after-radical-prostatectomy-importance-for-tailoring-and-individualizing-treatment
#20
Christoph Henkenberens, Thorsten Derlin, Frank M Bengel, Tobias L Ross, Hans-Jürgen Wester, Katja Hueper, Markus A Kuczyk, Hans Christiansen, Christoph A von Klot
PURPOSE: To evaluate the patterns of relapse and impact on the intended treatment when using (68)Ga-prostate-specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography (PET/CT) imaging for restaging of disease in patients with biochemical relapse after radical prostatectomy (RP) before salvage radiotherapy (sRT). METHODS: In all, 39 patients with biochemical recurrence after RP who had no primary indication for adjuvant RT due to the absence of biologically unfavorable disease (e...
November 13, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
keyword
keyword
5864
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"